BDNF and serum S100B levels according the spectrum of structural pathology in chronic pain patients

This study supports the hypothesis that BDNF and S100B neuromodulators present different serum levels according to the background disease associated to the chronic pain. These have the potential to be studied as markers of active disease or treatment evolution.
Source: Neuroscience Letters - Category: Neuroscience Source Type: research